

Research Point Global and WuXi CDS to rebrand as WuXi Clinical

10 May 2019 | News

The newly combined CRO specializes in collaborative partnering for global clinical trials



The mid-sized CRO market has seen a number of significant changes, and now the recently merged Research Point Global (RPG) and WuXi Clinical Development Services (CDS) are to rebrand as WuXi Clinical at DIA 2019. The event, held this year in San Diego, is widely seen by the industry as a key point in the CRO calendar at which major developments are announced, and with more of the drug pipeline emerging from small and mid-sized pharma, much attention has this year focused upon middle-tier CROs.

The newly combined contract research organization (CRO) employs some 1000 clinical research specialists across 20 global locations with two main hubs in the United States and China. WuXi Clinical will continue to focus on the expanding opportunities across small to mid-tier clients, offering tailored, customer-centric, full-service global clinical trial management. However, its expanded capabilities – including consistent global quality through unified processes – provide the additional benefit of serving as a seamless gateway into the recently evolved clinical trial landscape in China.

RPG has over 20 years of pedigree designing and implementing global clinical trials and capabilities spanning some 60 countries. The company brings long established, closely interwoven strategic partnerships with local experts from countries across North America, Europe, and Asia Pacific. WuXi CDS, the China-based CRO has deep regulatory knowledge within China and has undergone substantial growth in revenue, client base, and expertise over the past year. Coupled with WuXi's some 2000-member clinical research coordinator team (SMO services organization), WuXi Clinical can provide all aspects of clinical trial management necessary to successfully include China in global development plans.

“One of the main reasons we knew straight away that this union was going to be successful was the shared values of our Austin and Shanghai leadership teams. Both RPG and CDS had extremely client-centric approaches; this really set us apart from our competitors and is ingrained in the company's character. We act as a natural extension of our client's in-house clinical team, providing executive level support to successfully deliver global trials on or ahead of schedule. Our goal as WuXi Clinical is to continue to work with our client partners to be greater than the sum of our parts. In fact, our new company strategy is entirely focused around how we can work ‘better together’” commented Becky Carpenter, Head of North America/Euro Operations at WuXi Clinical.

By combining with WuXi CDS, the company has further enhanced capacity to provide tailored services, and serve as the gateway CRO to and from the U.S. and China.

“This is a hugely exciting time for WuXi Clinical as we bring together our focus on providing a very collaborative customer

approach, coupled with additional resources. Our targets for this year are to cement our offering amongst mid-tier pharma, and we anticipate good traction in the market. In fact, we have regularly benefited from working with returning contacts in these firms, as they have come to rely upon our unique expertise to advance trials. With our combined capabilities, we now have a crucial role to play in maximizing new opportunities and working as a bridge between R&D markets in the US and China.” added Johnathan Lee, General Manager and Head of WuXi Clinical.

The newly launched WuXi Clinical has spent the last eighteen months fully harmonizing and completely integrating its internal capabilities, processes, and operations. WuXi Clinical will launch the new brand at DIA 2019 in San Diego, CA.